Replacement of α-galactosidase A in Fabry disease: Effect on fibroblast cultures compared with biopsied tissues of treated patients

Virchows Archiv

Volumn 452, Issue 6, 2008, Pages 651-665

  Keslová Veselíková, Jana ^a   Hůlková, Helena ^a   Dobrovolný, Robert ^a   Asfaw, Befekadu ^a   Poupětová, Helena ^a   Berná, Linda ^a   Sikora, Jakub ^a   Goláň, Lubor ^b   Ledvinová, Jana ^a   Elleder, Milan ^a  

^a Charles University in Prague and General University Hospital in Prague   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Galactosidase A deficiency; Clearance of storage lysosomes; Enzyme replacement therapy; Enzyme targeting; Persistent storage

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; LYSOSOME ENZYME;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; FIBROBLAST CULTURE; HEART LEFT VENTRICLE MASS; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; LYSOSOME STORAGE DISEASE; MALE; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT OUTCOME;

ALPHA-GALACTOSIDASE; BIOPSY; CELLS, CULTURED; FABRY DISEASE; FIBROBLASTS; GENE THERAPY; HUMANS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; MYOCARDIUM;

EID: 44449096508     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-008-0586-9     Document Type: Article

References (43)

1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967
2. Asfaw B, Ledvinova J, Dobrovolny R, Bakker HD, Desnick RJ, Van Diggelen OP, De Jong JG, Kanzaki T, Chabas A, Maire I, Conzelmann E, Schindler D (2002) Defects in degradation of blood group A and B glycosphingolipids in Schindler and Fabry diseases. J Lipid Res 43:1096-1104
3. Blom D, Speijer D, Linthorst GE, Donker-Koopman WG, Strijland A, Aerts JM (2003) Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha-galactosidase A mRNA. Am J Hum Genet 72:23-31
4. Bolte S, Cordelieres FP (2006) A guided tour into subcellular colocalization analysis in light microscopy. J Microsc 224:213-232
5. Boyer M, Townsend LE, Vogel LM, Falk J, Reitz-Vick D, Trevor KT, Villalba M, Bendick PJ, Glover JL (2000) Isolation of endothelial cells and their progenitor cells from human peripheral blood. J Vasc Surg 31:181-189
6. Brady RO, Schiffmann R (2000) Clinical features of and recent advances in therapy for Fabry disease. JAMA 284:2771-2775
7. Brenner BM, Grunfeld JP (2004) Renoprotection by enzyme replacement therapy. Curr Opin Nephrol Hypertens 13:231-241
8. Bright NA, Gratian MJ, Luzio JP (2005) Endocytic delivery to lysosomes mediated by concurrent fusion and kissing events in living cells. Curr Biol 15:360-365
9. Desnick R, Ioannou YA, Eng CM (2001) Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, VAlle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 3733-3774
10. Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, Elleder M, Karetova D, Pavlikova M, Hrebicek M (2005) Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med 83:647-654
11. Elleder M (2003) Sequelae of storage in Fabry disease-pathology and comparison with other lysosomal storage diseases. Acta Paediatr Suppl 92:46-53 discussion 45
12. Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O, Callaghan M, Desnick RJ (2001a) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68:711-722
13. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001b) Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345:9-16
14. Genzyme, Corporation (2001) Product Monograph, Enzyme replacement therapy for Fabry disease
15. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ, Lee P, Loew T, Vedder AC, Abichandani R, Wilcox WR, Guffon N (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547-1557
16. Hartree EF (1972) Determination of protein: a modification of the Lowry method that gives a linear photometric response. Anal Biochem 48:422-427
17. Hernandez DA, Townsend LE, Uzieblo MR, Haan ME, Callahan RE, Bendick PJ, Glover JL (2000) Human endothelial cell cultures from progenitor cells obtained by leukapheresis. Am Surg 66:355-358 discussion 359
18. Hille-Rehfeld A (1995) Mannose 6-phosphate receptors in sorting and transport of lysosomal enzymes. Biochim Biophys Acta 1241:177-194
19. Hollak CE, Vedder AC, Linthorst GE, Aerts JM (2007) Novel therapeutic targets for the treatment of Fabry disease. Expert Opin Ther Targets 11:821-833
20. Christensen EI, Zhou Q, Sorensen SS, Rasmussen AK, Jacobsen C, Feldt-Rasmussen U, Nielsen R (2007) Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol 18:698-706
21. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ (2001) Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 68:14-25
22. Kolter T, Sandhoff K (2006) Sphingolipid metabolism diseases. Biochim Biophys Acta 1758:2057-2079
23. Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, Geagan L, Qiu H, Seiger K, Barngrover D, McPherson JM, Edmunds T (2003) A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13:305-313
24. Lojda Z, Gossrau R, Schiebler TH (1979) Enzyme histochemistry. A laboratory manual. Springer, Berlin
25. Luzio JP, Pryor PR, Gray SR, Gratian MJ, Piper RC, Bright NA (2005) Membrane traffic to and from lysosomes. Biochemical Society Symposium, pp 77-86
26. Manders EMM, Verbeek FJ, Aten JA (1993) Measurement of colocalization of objects in dual-color confocal images. J Microsc-Oxford 169:375-382
27. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML (1981) Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 112:247-251
28. Morimoto S, Yamamoto Y, O, Brien JS, Kishimoto Y (1990) Distribution of saposin proteins (sphingolipid activator proteins) in lysosomal storage and other diseases. Proc Natl Acad Sci U S A 87:3493-3497
29. Murray GJ, Anver MR, Kennedy MA, Quirk JM, Schiffmann R (2007) Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 90:307-312
30. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H et al (1995) An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333:288-293
31. Rasband WS (1997-2006). "ImageJ", from http://rsb.info.nih.gov/ ij/
32. Rozenfeld PA, Croxatto O, Ebner R, Fossati CA (2006) Immunofluorescence detection of globotriaosylceramide deposits in conjunctival biopsies of Fabry disease patients. Clin Exp Ophthalmol 34:689-694
33. Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T, Chiba Y, Takashiba M, Jigami Y, Fukushige T, Kanzaki T, Itoh K (2006) Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 51:180-188
34. Seehafer SS, Pearce DA (2006) You say lipofuscin, we say ceroid: defining autofluorescent storage material. Neurobiol Aging 27:576-588
35. Schiffmann R, Murray GJ, Treco D, Daniel P, Sellos-Moura M, Myers M, Quirk JM, Zirzow GC, Borowski M, Loveday K, Anderson T, Gillespie F, Oliver KL, Jeffries NO, Doo E, Liang TJ, Kreps C, Gunter K, Frei K, Crutchfield K, Selden RF, Brady RO (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 97:365-370
36. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M (2006) Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch 448:337-343
37. Simionescu M, Gafencu A, Antohe F (2002) Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microsc Res Tech 57:269-288
38. Stern AS, Klotman ME, Ioannou YA, Burrow CR, Wilson PD, Klotman PE, Lipkowitz MS (2002) Polarity of alpha-galactosidase A uptake by renal tubule cells. Kidney Int 61:52-55
39. Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O, Callaghan M (2004) Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 122:900-908
40. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O, Callaghan M (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933-1946
41. TKT, Europe (2001) Information Brochure, Enzyme replacement therapies for Fabry disease.
42. Wenk J, Hille A, von Figura K (1991) Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues. Biochem Int 23:723-731
43. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65-74